The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Open accessAbstract
Background High-grade serous ovarian carcinoma (HGSOC) is characterized by TP53 mutations, DNA repair defects, and genomic instability. We hypothesized that prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type HGSOC. Methods In this open label, single centre, two-stage proof-of-concept phase 2 study, women aged 18 years or older with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma were enrolled. All patients must have had either a negative family history of hereditary breast and ovarian cancer or known BRCA wild-type for BRCA wild-type cohort. Other key eligibility criteria were an Eastern Cooperative Oncology Group performance status of 0 or 1 or 2, and adequate haematological, renal, and hepatic function. Patients received intravenous prexasertib 105mg/m2 once every 2 weeks until disease progression, unacceptable toxicity or patient withdrawal of consent. The primary endpoint was investigator-assessed tumour response per protocol based on Response Evaluation Criteria in Solid Tumors, version 1·1 in evaluable patients. The final analysis of this cohort is reported here. This ongoing trial is registered with ClinicalTrials.gov (NCT02203513) and enrolling the patients of BRCA mutation cohort. Findings Between January 2015 and November 2016, 28 women (median age 64-year-old [IQR 58–69·5], with median 5 prior systemic therapies [IQR 2·5–5]) were enrolled and received at least one dose of prexasertib. Eight of 24 evaluable patients had a partial response (PR; 33%, 95% CI: 16–55) and 50% had a GCIG CA125 response. The RR in the intention-to-treat population was 29% (8/28, 95% CI: 13–49). The common (>10%) grade 3 or 4 treatment-emergent adverse events were neutropenia (26 [93%] patients), thrombocytopenia (seven [25%] patients), and anaemia (three [11%] patients). Grade 4 neutropenia occurred in 22 (79%) patients after the first dose and was transient ≤ 7 days (median 6 days [IQR 4–8]) without growth factor support; the incidence of febrile neutropenia was 7% (2/28). Interpretation We demonstrate clinical activity of prexasertib in BRCA wild-type HGSOC, especially patients with platinum-resistant or refractory ovarian cancer. These results warrant further development for this unmet patient need. Funding Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citationHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455
Checkpoint kinase 1 in DNA damage response and cell cycle regulation
Patil, M., Pabla, N., & Dong, Z. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1307-3 · Cited by 317
Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1546 · Cited by 56
Self-citation
Cited by
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
Self-citationClinical and translational advances in ovarian cancer therapy
Konstantinopoulos, P. A., & Matulonis, U. A. (2023) · Nature Cancer · doi:10.1038/s43018-023-00617-9 · Cited by 394
The Fanconi Anemia Pathway in Cancer
Niraj, J., Färkkilä, A., & D'Andrea, A. D. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050422 · Cited by 376
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Yang, L., Xie, H.-J., Li, Y.-Y., Wang, X., Liu, X.-X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 304
Metadata
- Authors
- Lee, J.-M., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., Bagheri, M. H., Botesteanu, D.-A., Steinberg, S. M., Minasian, L., Ekwede, I., & Kohn, E. C.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 19
- Issue
- 2
- Pages
- 207-215
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2783907570
- Cited by
- 209
- References
- 7
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30009-3
- The paper
- Lee, J.-M., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., Bagheri, M. H., Botesteanu, D.-A., Steinberg, S. M., Minasian, L., Ekwede, I., & Kohn, E. C. (2018). Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30009-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.